Drug Profile


Alternative Names: Deltyba; OPC-67683; UNII-8OOT6M1PC7

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class 2 ring heterocyclic compounds; Antituberculars; Nitroimidazoles; Oxazoles; Phenyl ethers; Piperidines; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Tuberculosis

Most Recent Events

  • 24 Feb 2016 Preregistration for Tuberculosis (Combination therapy) in China, Hong Kong, Indonesia, Turkey, Philippines (PO)
  • 15 Jul 2015 Registered for Tuberculosis (Combination therapy) in South Korea (PO)
  • 15 Jul 2015 Efficacy data from a post-hoc subset analysis of a phase II trial in Tuberculosis (Combination therapy) released by Otsuka Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top